Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression
- PMID: 11926889
- DOI: 10.1001/jama.287.13.1653
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression
Abstract
Context: Pramipexole and levodopa are effective medications to treat motor symptoms of early Parkinson disease (PD). In vitro and animal studies suggest that pramipexole may protect and that levodopa may either protect or damage dopamine neurons. Neuroimaging offers the potential of an objective biomarker of dopamine neuron degeneration in PD patients.
Objective: To compare rates of dopamine neuron degeneration after initial treatment with pramipexole or levodopa in early PD by means of dopamine transporter imaging using single-photon emission computed tomography (SPECT) with 2beta-carboxymethoxy-3beta(4-iodophenyl)tropane (beta-CIT) labeled with iodine 123.
Design: Substudy of a parallel-group, double-blind randomized clinical trial.
Setting and patients: Eighty-two patients with early PD who were recruited at 17 clinical sites in the United States and Canada and required dopaminergic therapy to treat emerging disability, enrolled between November 1996 and August 1997.
Interventions: Patients were randomly assigned to receive pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42), or carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40). For patients with residual disability, the dosage was escalated during the first 10 weeks, and subsequently, open-label levodopa could be added. After 24 months of follow-up, the dosage of study drug could be further modified.
Main outcome measures: The primary outcome variable was the percentage change from baseline in striatal [(123)I]beta-CIT uptake after 46 months. The percentage changes and absolute changes in striatal, putamen, and caudate [(123)I]beta-CIT uptake after 22 and 34 months were also assessed. Clinical severity of PD was assessed using the Unified Parkinson Disease Rating Scale (UPDRS) 12 hours off anti-PD medications.
Results: Sequential SPECT imaging showed a decline in mean (SD) [(123)I]beta-CIT striatal uptake from baseline of 10.3% (9.8%) at 22 months, 15.3% (12.8%) at 34 months, and 20.7% (14.4%) at 46 months-approximately 5.2% per year. The mean (SD) percentage loss in striatal [(123)I]beta-CIT uptake from baseline was significantly reduced in the pramipexole group compared with the levodopa group: 7.1% (9.0%) vs 13.5% (9.6%) at 22 months (P =.004); 10.9% (11.8%) vs 19.6% (12.4%) at 34 months (P =.009); and 16.0% (13.3%) vs 25.5% (14.1%) at 46 months (P =.01). The percentage loss from baseline in striatal [(123)I]beta-CIT uptake was correlated with the change from baseline in UPDRS at the 46-month evaluation (r = - 0.40; P =.001).
Conclusions: Patients initially treated with pramipexole demonstrated a reduction in loss of striatal [(123)I]beta-CIT uptake, a marker of dopamine neuron degeneration, compared with those initially treated with levodopa, during a 46-month period. These imaging data highlight the need to further compare imaging and clinical end points of PD progression in long-term studies.
Comment in
-
Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.JAMA. 2002 Jul 17;288(3):311-2; author reply 312-3. JAMA. 2002. PMID: 12117386 No abstract available.
-
Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.JAMA. 2002 Jul 17;288(3):312; author reply 312-3. JAMA. 2002. PMID: 12117387 No abstract available.
Similar articles
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
-
Levodopa and the progression of Parkinson's disease.N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Clinical Trial.
-
Do dopamine agonists or levodopa modify Parkinson's disease progression?Eur J Neurol. 2002 Nov;9 Suppl 3:15-22. doi: 10.1046/j.1468-1331.9.s3.2.x. Eur J Neurol. 2002. PMID: 12464117 Review.
-
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.JAMA. 2000 Oct 18;284(15):1931-8. doi: 10.1001/jama.284.15.1931. JAMA. 2000. PMID: 11035889 Clinical Trial.
-
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.Mov Disord. 1999 Nov;14(6):940-6. doi: 10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y. Mov Disord. 1999. PMID: 10584667 Clinical Trial.
Cited by
-
Clinical severity in Parkinson's disease is determined by decline in cortical compensation.Brain. 2024 Mar 1;147(3):871-886. doi: 10.1093/brain/awad325. Brain. 2024. PMID: 37757883 Free PMC article.
-
Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.Neurology. 2023 Sep 19;101(12):e1196-e1205. doi: 10.1212/WNL.0000000000207621. Epub 2023 Jul 31. Neurology. 2023. PMID: 37524532
-
Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia.Cells. 2023 Jul 14;12(14):1859. doi: 10.3390/cells12141859. Cells. 2023. PMID: 37508522 Free PMC article.
-
Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit.Front Neurosci. 2022 Nov 24;16:1048945. doi: 10.3389/fnins.2022.1048945. eCollection 2022. Front Neurosci. 2022. PMID: 36507343 Free PMC article.
-
First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study.J Pers Med. 2022 Aug 9;12(8):1300. doi: 10.3390/jpm12081300. J Pers Med. 2022. PMID: 36013249 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical